Galderma's Restylane Lyft Gains FDA Approval for Chin Augmentation

Galderma, a leading dermatology business, has announced a significant expansion to its aesthetic portfolio with the US Food and Drug Administration (FDA) approval of its ‘Restylane Lyft with Lidocaine’ product. This latest approval specifically targets chin augmentation, designed to improve the chin profile in patients aged 21 and older who present with mild-to-moderate chin retrusion. The introduction of this product offers a new, minimally invasive option for individuals seeking to enhance their lower facial contours and achieve a more balanced profile.

This FDA approval underscores Galderma's unwavering commitment to advancing its Injectable Aesthetics portfolio, which the company proudly claims as the broadest on the market. Bill Andriopoulos, Galderma’s Vice President of Medical Affairs, emphasized the strategic importance of this development, stating, "This approval reinforces our commitment to advancing our Injectable Aesthetics portfolio - the broadest on the market - to meet the diverse needs of patients. By expanding how innovations like Restylane Lyft can be used, we aim to empower aesthetic practitioners to achieve their patients' unique aesthetic goals with enhanced flexibility and precision." This move aims to provide practitioners with more versatile tools to cater to a wider array of patient aesthetic desires.

The Restylane portfolio from Galderma is renowned for its comprehensive range of hyaluronic acid (HA) injectables, featuring both flexible and firm gel formulations tailored to deliver personalized aesthetic outcomes. Restylane Lyft, in particular, stands out for its development with NASHA® technology. It is characterized as a firmer gel with minimal modification, meticulously engineered to provide a natural look and feel. This technological foundation allows for effective volume restoration and contouring, making it a suitable choice for structural enhancements like chin augmentation.

The FDA's decision to approve Restylane Lyft with Lidocaine for chin augmentation was rigorously based on the compelling results of a pivotal clinical trial. This study effectively demonstrated the product's safety and effectiveness in significantly improving chin projection three months after the initial injection. Furthermore, the improvements were sustained in the majority of patients throughout a 12-month period, highlighting the long-lasting effects of the treatment. Crucially, the trial also confirmed a favorable safety profile, reporting no unexpected or serious adverse events related to the product, thereby reassuring both practitioners and patients of its reliability.